Peptide Works
Research-Grade Peptide Supplier
Peptide Works
Research-Grade Peptide Supplier
A worldwide supplier of high-purity research peptides for laboratories, academic research groups and independent investigators — built for work that cannot afford a bad batch.
Peptide Works is a worldwide supplier of high-purity research peptides to laboratories, academic research groups and independent investigators.
That sentence is short, and it should be. It describes the whole of the role. We are a peptide synthesis laboratory. We supply peptides for research purposes. That focus is what allows us to verify what is in every vial before it leaves the facility. We ship it. We track it. And although we are not travelling with the parcel, we stay reachable if something goes wrong along the way.
There is no side business here. No second venture, no adjacent product line quietly paying the bills. Peptides are what we do, and they are all we do.
The people who buy from us are not window shoppers. They are running assays, validating protocols and building on results that others will later try to reproduce. To them, a supplier is not a storefront. A supplier is a variable. And an uncontrolled variable is the fastest way to lose a month of work.
Look at the structure of the problem for a moment. You design a study. You control for temperature, for timing, for handling, for operator technique. You write each step down so that another researcher, in another laboratory, can repeat it exactly. And then, right in the middle of all that careful control, you place a vial that arrived in the post from people you have never met, from a facility you have never inspected. That vial is an assumption. Every inference downstream of it rests on assumptions about what the vial actually contains.
Peptide Works was founded on that observation. Everything else on this page follows from it.
All products supplied by Peptide Works are intended for laboratory research or further evaluation only.
Peptide Works did not begin with a business plan. It began with frustration.
Anyone who has ordered research peptides over the past decade will recognise the pattern. You find a supplier. The first order arrives and it is fine. The second order arrives and it is good. Then the third order behaves differently — only slightly, but unmistakably — and now you have a problem, because you cannot tell whether the difference sits in your work or in the vial.
So you email the supplier. Three days later a one-line reply arrives, answering a question you never asked. You ask again. The thread goes quiet.
Or the certificate of analysis turns up as a PDF with a purity figure on it and a laboratory name at the bottom, but no batch number that matches the vial in your hand. It might belong to your shipment. It might belong to a shipment from eight months ago. There is no way to tell, and the supplier does not appear to think that matters.
Or the shipment simply disappears in transit. Tracking stops somewhere inside a customs facility. Nobody at the company seems to know how to deal with that uncertainty, and nobody seems especially keen to find out.
None of this is exotic. Ask anyone who has spent time ordering research materials and you will hear a version of the same three stories. At some point, the unreliability started to look like something worth building a company around — not because it was rare, but because of how normal it had become, and how many researchers had quietly accepted that suppliers are unreliable and had built that unreliability into their schedules. Order early. Order double. Assume some of it will be wrong.
Look closely at what that adaptation actually costs. Ordering early means tying up capital in material that sits in a freezer losing value. Ordering double means paying twice over to hedge against someone else's incompetence. Assuming some of it will be wrong means building a tolerance for error into work whose entire purpose is to eliminate error. And the worst cost is the invisible one: the strange result that was written off as a methodological fault and quietly filed away, when the real explanation was a vial that did not contain what the label promised.
That is a bad equilibrium. It slows everything down, it costs more, and it makes reproducibility harder for everybody. We kept asking a simple question. Why does a supplier have to be like that?
There was nothing clever about the plan behind Peptide Works. The unglamorous parts of the business were always going to be the important parts.
Anyone can build a catalogue. The hard work sits in the places nobody photographs: batch tracking, cold-chain handling, third-party verification with paperwork that actually matches the product, packaging that survives a long-haul flight and a hot loading bay, and a support inbox staffed by real people who know what a certificate of analysis is and how to read one.
There is a reason those things get neglected. None of them convert. A well-designed website converts. A vial photographed under studio lighting converts. A chain-of-custody record converts nothing, because nobody ever sees it, and the person who benefits from it never learns that anything good happened. They simply had another week in which nothing went wrong. Commercial pressure points away from quality infrastructure — gently, downwards, permanently — and a supplier who does not actively resist that pressure will drift.
So that is where we put the effort. Peptide Works was designed backwards, starting from the logistics. The catalogue came afterwards.
It began with questions that have deeply unglamorous answers. What is this material, and where can it be traced back to? Who tests it, and does that person have an interest in telling us what we want to hear? How is it stored between the moment it is tested and the moment it is packed? How hot does it get on the fourth day of a delay? And when the honest answer to a question is that nobody knows, who picks up the phone?
Every one of those questions marks a place where a supplier can shave costs without the customer noticing for months — and possibly never, because the failure shows up as an odd experimental result rather than an obvious defect. That is precisely why we treated them as the foundation rather than the fine print.
This is not a story about a garage or an epiphany in front of a whiteboard. What happened is simpler than that. People who had been on the receiving end of bad supply for long enough decided to run it properly. They ran it. They kept running it. And it grew because researchers told other researchers. That is the honest version.
To be the leading supplier of high-purity peptides for scientific discovery, delivering trusted service and dependable global delivery to researchers.
In practice, we aim to be the most boring part of a researcher's day.
That is not false modesty. It is a real standard, and it is a demanding one. The peptide arrives on schedule. It is what the label says it is. The documentation matches the vial. Nobody has to think about us, chase us, or plan around us. The researcher simply gets on with the research.
A completely successful supplier is, in effect, a supplier who disappears. That is the target.
The word invisible sounds passive, and it is anything but. To stay invisible you have to be right every single time. One late shipment and you are visible. One mismatched batch number and you are suddenly impossible to ignore — you are the subject of an internal email, a phone call, and a conversation about whether to find a different supplier altogether. For a supplier, visibility is almost always a symptom of failure. The only way to avoid it is to be relentless about the things that cause it.
To be the supplier researchers choose by default — a position earned through quality, consistency and service rather than promised through marketing.
Default status cannot be bought and it cannot be advertised into existence. It accumulates. It happens when a laboratory has ordered from you eleven times, and eleven times it was fine, and by the twelfth order nobody bothers checking whether another supplier might do better, because there is no reason for concern.
Getting there takes consistency held for a long time, in an industry where consistency is scarce. We would far rather be the supplier a laboratory has relied on for years than the one that made the biggest noise at launch.
That carries an implication, and we would rather put it on the page than leave it unspoken. A single borderline batch — one we knew was marginal and shipped anyway because month-end was approaching and the numbers were short — can undo years of accumulated trust. Every supplier eventually faces that choice. For most of them, it is a recurring fight. The ones who hold the line survive for decades. The others enjoy one very good quarter and then spend years chasing their reputation around the block.
We would rather lose a sale than lose the reason anyone buys from us in the first place. That is a practical position, not a moral one. A sale is worth what it is worth. A reputation is worth every sale that comes after it.
Peptide Works maintains a broad and varied catalogue of research peptides across multiple formats.
Our peptides are supplied as lyophilised material in vials, as prepared blends and stacks, in capsule form, as nasal sprays, and as pre-mixed pens.
That range does not exist to make the catalogue look bigger. It exists because different research workflows have different requirements for how material is presented, and forcing a laboratory into the wrong format wastes both their time and their material.
Format is usually treated as an afterthought, so it is worth explaining why it is not.
Lyophilised vials remain the benchmark format, and for good reason. Freeze-dried material is stable, it carries no unusually strict storage constraints, and it gives the researcher complete control over reconstitution — solvent, concentration, volume, everything. This is the format you reach for when a protocol has to be defined precisely and repeated identically every time. It also has a long, predictable shelf life when stored correctly, which matters a great deal to a group ordering on a grant cycle rather than a weekly cycle. Lyophilisation effectively puts an experiment on pause inside a vial, and lets the researcher restart it whenever they choose.
Blends and stacks exist because preparing several compounds separately offers many opportunities to get something wrong. Where a research protocol calls for a specific combination, supplying it as a single, already-tested product removes several manual steps that would otherwise introduce variability. Every additional preparation step is a weighing, a transfer, a pipetting — and each one carries an error term that compounds through the workflow. Removing steps is not laziness. It is variance reduction, and variance reduction is most of what good experimental practice amounts to.
Capsule formats matter wherever a study design depends on identical, discrete, pre-measured units. The entire point is uniformity between units, and uniformity is a manufacturing problem rather than a research problem. If unit fourteen contains meaningfully less than unit three, the study carries a confound so damaging that no amount of statistical care can remove it — and the researcher has no way of knowing it is there. The supplier has to build that uniformity into the process upstream, because there is no way to inspect for its absence downstream.
Nasal spray formulations are used in research settings where the route of administration is itself the subject of study. Consistency has to hold across both the formulation and the device. Otherwise the route stops being an independent variable and becomes a source of noise instead.
Where reconstitution is a bottleneck, or a risk to repeatability, pre-mixed pens remove preparation steps entirely. They exist for the same reason blends do. Every operation a researcher does not have to perform is an operation that cannot be performed inconsistently.
One idea runs through all of it. Format is not packaging. Format is part of experimental method, and a supplier who treats it as a merchandising decision has misunderstood their own product.
This page will not walk you through the catalogue compound by compound. Every peptide we list has its own product page, documentation and certificate of analysis, and that is where those details belong. For example, researchers looking for product-specific information can review the Peptide Works LL-37 Peptide page. An About page is not the right place for detailed compound information.
We also will not tell you what any individual peptide does, how it might be used, or what effects it may produce. Doing so would be irresponsible and would fall well outside what we are here for. We supply materials for research. The research itself — what it asks and what it finds — belongs to the researcher. A vendor who starts explaining the science has quietly stepped out of the role of vendor and into a role that carries a much heavier duty to be right.
This is the section we spend the most time on, because it is the section that decides everything else.
Peptide Works supplies peptides at 99% purity or above for standard sequences, and 98% purity or above for structurally complex peptides.
The gap between those two numbers is not a hedge, and it is worth explaining rather than glossing over.
Peptide synthesis proceeds one step at a time. Amino acids are added in sequence, and at every coupling step the efficiency is slightly less than perfect. For a short, well-behaved sequence, those small imperfections accumulate very little, so 99% purity is a reasonable and achievable target. For longer sequences — or sequences that are difficult to assemble, such as those with aggregation-prone regions or secondary structure that interferes with clean elongation — the same per-step efficiency produces a population of products sitting very close together in chemical space: deletions, truncations and side-products similar enough to the target that separating them is far from trivial.
The arithmetic here is unforgiving, and it deserves to be stated plainly. A coupling efficiency that sounds excellent in isolation becomes a serious limitation once it is raised to the power of the sequence length. Length is not a secondary consideration. It is the primary one. And the impurities left behind are not inert bystanders. A deletion sequence is still a peptide, similar in mass to the target, and it will co-elute with the target unless the purification is genuinely good. Removing it is a real engineering problem with real costs — which is exactly why pretending otherwise is how suppliers end up publishing numbers they cannot support.
A supplier claiming 99% or better on everything, across the board, without qualification, is either using a definition of purity that nobody else would recognise, or is not being straight with you. It is easier to give two numbers and explain the difference than to give one number and hope nobody asks.
We know that publishing a second figure makes our headline number look slightly worse than a competitor's. We have made our peace with that. We would rather work with researchers who read the second number and immediately ask why it is there.
Every batch is tested. Not every product line — every batch.
This distinction gets blurred constantly in our sector, and the blur is not accidental. A supplier can test one batch of a compound, obtain a good result, and then reuse that same certificate for every subsequent batch of that compound for the next two years. Technically, they tested it. In practice, the document tells you almost nothing about the vial in your hand.
A certificate of analysis that cannot be traced to the material you actually received is meaningless. Anything less than traceability is decoration.
Our batches are tested and certified by independent third-party laboratories. The important word in that sentence is independent.
In-house testing is not worthless. We run our own tests, and they catch problems early. But there is a structural conflict at the centre of in-house testing: the party being tested is also the party doing the testing. Saying so is not an accusation. It is simply how incentives work, and a quality system that does not account for it is not really a quality system.
The dangerous thing about this conflict is that nobody has to lie for it to cause harm. It works through a hundred small, defensible decisions. A borderline peak — not a clear failure, but not clean either — gets the benefit of the doubt. A retest gets ordered when the first result is poor, but not when it is good. An odd reading gets attributed to the instrument, because the instrument has been behaving strangely, and that is a perfectly reasonable thing to say. None of those steps is fraud. Together they amount to a slow, invisible erosion of the foundation, and everyone involved would pass a lie detector test.
Because our batch testing is carried out by a third-party laboratory, the people doing it have no commercial stake in the outcome. The analyst runs the analysis and reports the result. If a batch does not meet specification, it does not meet specification. That result is final, and we cannot quietly overturn it. That is the entire point of the arrangement. It costs us something, and its value lies precisely in the fact that it is inconvenient for us.
Testing typically means purity by analytical HPLC together with identity confirmation by mass spectrometry — confirming that the peptide really is the sequence it is supposed to be, and not simply a very pure sample of something else. Purity without identity is just a number. A vial can be 99.8% pure and still contain a compound you were not asking for, and a purity assay on its own will happily describe that vial as excellent. The two tests answer different questions, and a supplier running only one of them is answering only half of yours.
We provide a certificate of analysis with every batch, and every batch we supply can be traced back to its source.
If the paperwork cannot be matched to the vial, the paperwork is not evidence. It is a formality. The certificate carries a batch number, and that number matches the number printed on the label of the vial you receive. That is what turns a document into evidence — and it is also why, if something ever looks wrong, we would like to hear about it from you before anyone else does.
Purity at the point of manufacture is not the same thing as purity at the point of use. A supplier who talks about one while ignoring the other is telling half the story.
Peptides degrade. They are sensitive to temperature, moisture, light and freeze-thaw cycles. A peptide that leaves a facility at 99.4% and then sits on a warm shelf for two weeks is no longer the substance described on its certificate. The certificate has not been falsified. It was true on the day it was issued. It has simply been made irrelevant — which, from the researcher's point of view, amounts to the same thing.
This is the least discussed failure mode, and it does the quietest damage, because it is invisible. A degraded vial does not announce itself. It looks correct. It is labelled correctly. It carries a certificate saying all the right things. And it will return a result that is slightly, inexplicably wrong, while the researcher spends three weeks hunting for a flaw in their own technique.
So we treat storage and cold-chain integrity as part of the quality system rather than as a shipping detail. Storage conditions are defined for lyophilised material. Packaging is chosen to hold those conditions in transit, including the parts of transit that are outside our control — the customs holds, the depot backlogs, the hot afternoon on a loading dock. We specify packaging for the journey a shipment may realistically take, not the journey we would like it to take. The vial that reaches you should be the vial described on your certificate.
Batch-to-batch consistency is the last piece, and it is the one researchers care about most once they have been burned.
One good batch is an event. A hundred consistent batches is a system. Anyone can get lucky once. We are strict about process control, about specification, and about independent testing on every batch, because consistency is not something you arrive at. It is something you maintain indefinitely, and the moment you stop maintaining it, it quietly stops being true.
Batch nine should behave exactly like batch one. If it does not, the problem is ours, and we want to know about it.
Support is a relationship. We know that sounds like something every company says, so here is what it actually means in practice. Researchers can also visit the Peptide Works FAQs for answers to common questions about shipping, orders, products, storage, customs and returns.
You can ask us questions before you place an order. What is the purity specification for this sequence? Can I see the certificate of analysis for the current batch? How is this shipped, and what happens if it is held in customs? What is the storage guidance? Those are fair questions with legitimate answers, and nobody should have to open a ticket and wait four days to get one.
Our support team can read a certificate of analysis. That is a low bar, and a surprising number of suppliers fail to clear it. Anyone answering a question about a chromatogram, or about how a purity figure was arrived at, should not be reading from a script. This is not a point of pride. It is a practical requirement, because only a technically literate support function can recognise when something has genuinely gone wrong. A complaint handled by someone reading from a template gets matched to the nearest template. A complaint handled by someone who understands the analysis prompts a different thought entirely: that should not happen — what in our process could have produced this? A defect can only be caught if somebody notices it in time.
We are still here after delivery. This is the point at which most suppliers lose interest, because the transaction is complete and the incentive to care has evaporated. If your shipment arrives damaged, if the paperwork does not line up, if something about the material looks wrong — that conversation is not an inconvenience to us. It is the most valuable conversation we have, because it is the only way we learn about problems in our own process.
We would far rather hear about an issue than not hear about it. A complaint is information. A silent, unhappy customer is a defect we never got the chance to correct — and, worse, a fault that is almost certainly still sitting in the system, waiting to reach someone else.
Shipping temperature-sensitive research materials internationally is a genuine logistical problem. We would rather describe it accurately than promise a magic solution.
Shipments are packed to hold the conditions the material needs across a full transit cycle, including the delays nobody planned for. Cold-chain packaging is specified for the journey as it actually happens, not for an idealised version of it. There is a real difference between a three-day transit package that spends three days in transit and one that was designed for a three-day window but took seven — and the second case happens often enough that failing to design for it would be negligent.
Orders are trackable. You should be able to see where your shipment is without emailing anyone to ask. Visibility is not a courtesy. A researcher who has planned an entire week of work around a delivery deserves to know whether that plan still holds, and should not have to request an update to find out.
Packaging is plain and unbranded. No further commentary is needed here. Researchers understand why this matters.
These are international shipments. They cross borders, and borders have rules. Every jurisdiction has its own, those rules change regularly, and no supplier gets to dictate them. What we can control is the paperwork, and we do that properly. Very few customs delays are caused by scrutiny of the material itself. Most are caused by a form that was filled in badly, or not at all. Correct documentation, submitted correctly the first time, is the cheapest transit insurance available — and it is remarkable how many suppliers treat it as an administrative afterthought to be handed to whoever happens to be free.
Live shipping rates are calculated at checkout, and shipping protection is available. Transit is the stretch of the process furthest from our hands, and protection exists so that a problem there does not turn into a loss for the researcher. The principle is simple. A failure in our supply chain should be absorbed by our supply chain, not quietly pushed onto the person waiting for the parcel.
We are not going to claim that nothing ever goes wrong in international logistics. Things go wrong in international logistics constantly. Aircraft are grounded, depots flood, ports congest, and somewhere a customs officer decides that today is the day for a thorough inspection. What we will say is this: when something does go wrong, there is a person at Peptide Works who takes responsibility for fixing it, and who will come back to you. The measure of a supply chain is not that it never fails. It is what happens in the hour after it does.
Not purity we assert. Purity independently tested on your batch, documented on a certificate that carries your batch number. Every claim we make is auditable, because a claim that cannot be checked is not really a claim. If we expect you to trust the work, you should be able to verify the work.
The asymmetry here is worth naming plainly. An unverified supplier is asking you to take their word for it, and their word costs them nothing to give. A supplier who sends every batch to an outside laboratory has paid for someone with no loyalty to them to have the final say. Those are not two versions of the same claim. They are different in kind.
A wide range of compounds across multiple formats means that a research group does not have to split its supply chain between four vendors simply to obtain what a single protocol requires. Researchers can review individual catalogue pages, including https://peptide-works.com/vip-peptide/, for the relevant product-specific information and available documentation. Every additional vendor in a workflow brings another set of standards, another documentation convention and another point of failure. Consolidation is not merely convenient. It is a quality measure, and one of the few available to a research group with no capacity to audit its suppliers directly.
Real people rather than bots, technically literate, and reachable before and after the sale. Nobody at Peptide Works is measured on how quickly they close a ticket. Speed of closure is the worst possible metric for a support function, because the fastest way to close a ticket is to make the customer give up.
Global shipping, packaged correctly, sent with tracking and protection, with a named human on our side when something goes wrong.
That is the whole list. It could be longer, but a longer list would not make it more true. A heavy list of differentiators is usually a sign that no single item on it is strong enough to stand as a differentiator on its own, and researchers can spot that as easily as anyone.
We would rather be direct about this than soften it.
All products supplied by Peptide Works are for laboratory research and development use only. We supply nothing for human or animal consumption, ingestion or application of any kind.
We do not describe how to use these materials. We do not provide protocols, dosing information or administration instructions. We do not discuss effects, outcomes or benefits, and we make no medical, clinical, therapeutic or curative claims of any kind. Nothing on our websites is intended to diagnose, treat, cure or prevent any disease.
This is not a legal notice buried in a footer to satisfy a lawyer. It is a line we hold, and it shapes what we write, how our products are described and what our team is able to discuss. It constrains our marketing, it constrains our product pages, and it constrains our support conversations. Those constraints are commercially painful. We live with them.
There is a version of this industry that treats the research-use framing as a formality — something to print in small type and then contradict with every other sentence on the page. We are not that supplier, and we would rather the researchers who work with us never had to deal with one. A supplier who is careless about this will be careless about other things too, and researchers are right to make that connection. A company willing to stretch its own stated limits to close a sale is the same company that will ship a borderline batch at the end of a slow month. The behaviour comes from exactly the same place.
Materials for research. Supplied properly. That is the entire remit.
We have no plans to become anything else.
There is a well-worn path where a supply company grows comfortable, decides that supply is a low-margin model, and starts reaching towards something adjacent and more lucrative. We have watched that happen, and we have watched what it does to the supply operation that was there first. Attention is finite. Once the interesting work is happening elsewhere in the building, the supply side stops being where the best people want to be, and it begins to rot — not dramatically, but steadily, in the quiet way that quality systems always rot when nobody is watching them.
Peptide Works will remain a supplier. What we want to improve is the supply itself: more batches independently verified, cold-chain performance that is both tighter and less costly, documentation that is faster and clearer, better regional coverage where supply is thin, and a support function that grows more knowledgeable rather than more automated.
None of that makes for an exciting announcement. It is the right work regardless.
Research is hard, in the way that most worthwhile fields are hard. The experiment is uncertain, the funding is limited and the timeline is never generous. The substance in the vial should not be one more thing to worry about.
That is why Peptide Works exists. High-purity peptides, verified batch by batch by independent laboratories, documented so that the paperwork matches the product, packaged to survive the journey, shipped worldwide, and supported by people who are still there after you have signed for the parcel.
We are judged on whether the material was right and whether it arrived. So are you. That is what makes the relationship work.
All products on this website are for research use only. Everything purchasable on this site, and everything supplied by Peptide Works, is intended solely for laboratory research and development.
These products are not designed to be consumed or ingested by any human or animal. All information, statements and products on this site are intended for research and educational purposes only, and are not intended to diagnose, treat, cure or prevent any disease.